Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valemetostat plus pembrolizumab versus pembrolizumab alone in PD-L1-high advanced or metastatic NSCLC
jRCT2031240572Phase 2Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- May 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 2, randomised, open-label trial of valemetostat and pembrolizumab in non-small cell lung cancer (NSCLC) and bronchial carcinoma (3 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Number of Participants with Dose-Limiting Toxicities, Number of Participants with Treatment-Emergent Adverse Events and 1 more. Started May 2025; status: active, not recruiting.
02
Drugs
valemetostatpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)bronchial carcinoma
Beyond the preview
Go deeper on jRCT2031240572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240572.